Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.18
(
0.06%
)
Bitcoin
78,503.95
(
-0.05%
)
News Focus
News Focus
Post# of 9090
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biotech_researcher post# 301

Thursday, 11/30/2017 6:30:06 PM

Thursday, November 30, 2017 6:30:06 PM

Post# of 9090
RVNC advances cervical-dystonia program to phase-3 (11/29/17 PR):

http://investors.revance.com/releasedetail.cfm?ReleaseID=1050212

A single global phase-3 program will be conducted to satisfy both the FDA and EMA.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote